5
EFFECT OF EMPAGLIFLOZIN ON LIVER FAT IN METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE PATIENTS WITHOUT DIABETES MELLITUS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Date
May 18, 2024
Background: While sodium-glucose cotransporter 2 inhibitors improves cardiovascular and renal outcomes irrespective of diabetes mellitus (DM) status, their effects in metabolic-dysfunction associated steatotic liver disease (MASLD) patients without diabetes mellitus (DM) are unknown.
Methods: This was an investigator-initiated, double-blind, randomized, placebo-controlled trial recruiting adult subjects from the community between March 2021 and April 2022. Eligible subjects had magnetic resonance imaging-proton density fat fraction [MRI-PDFF] ≥5% but without DM (fasting plasma glucose <7mmol/L and HbA1c <6.5%). They were randomly allocated to receive empagliflozin 10mg daily or placebo (1:1 ratio) for 52 weeks (end of treatment, EOT). MRI-PDFF was conducted at baseline and EOT. Exclusion criteria included DM, alcoholism, concurrent chronic liver diseases, decompensated cirrhosis, prior malignancy, pregnancy and contraindications to empagliflozin use and MRI. The primary outcome was the difference in changes of MRI-PDFF between two groups at EOT. Secondary outcomes were resolution of hepatic steatosis (MRI-PDFF <5%) and changes of anthroprometic and laboratory parameters at EOT. All outcomes were based on intention-to-treat analysis.
Results: Of 98 recruited subjects (median age 55.7years [IQR:49.5-63.4]; male:54 [55.1%]), 97 (empagliflozin:49; placebo:48) had MRI-PDFF repeated at EOT. The median MRI-PDFF at baseline was 9.7% and 9.0%, respectively. At EOT, empagliflozin group had a greater drop in median MRI-PDFF than placebo group (–2.49% vs –1.43%; p=0.025), with a trend of resolution of hepatic steatosis (44.9% vs 28.6%; p=0.094). Empagliflozin group had a greater drop in body weight (–2.7 vs –0.2kg; p<0.001), waist circumference (–2.0 vs –0.4cm; p=0.015), fasting glucose (–0.3 vs 0mmol/L; p<0.001) and ferritin (–126 vs –22pmol/L; p=0.030) compared with placebo group.
Conclusions: Treatment with empagliflozin for 52 weeks reduces hepatic fat content in MASLD subjects without DM, together with reduction in serum ferritin, fasting glucose and anthropometric parameters (body weight and waist circumference).
Funding: This work was funded by a research grant from the General Research Fund, Research Grant Council, The Government of the Hong Kong Special Administrative Region (Ref: 17110420).
Methods: This was an investigator-initiated, double-blind, randomized, placebo-controlled trial recruiting adult subjects from the community between March 2021 and April 2022. Eligible subjects had magnetic resonance imaging-proton density fat fraction [MRI-PDFF] ≥5% but without DM (fasting plasma glucose <7mmol/L and HbA1c <6.5%). They were randomly allocated to receive empagliflozin 10mg daily or placebo (1:1 ratio) for 52 weeks (end of treatment, EOT). MRI-PDFF was conducted at baseline and EOT. Exclusion criteria included DM, alcoholism, concurrent chronic liver diseases, decompensated cirrhosis, prior malignancy, pregnancy and contraindications to empagliflozin use and MRI. The primary outcome was the difference in changes of MRI-PDFF between two groups at EOT. Secondary outcomes were resolution of hepatic steatosis (MRI-PDFF <5%) and changes of anthroprometic and laboratory parameters at EOT. All outcomes were based on intention-to-treat analysis.
Results: Of 98 recruited subjects (median age 55.7years [IQR:49.5-63.4]; male:54 [55.1%]), 97 (empagliflozin:49; placebo:48) had MRI-PDFF repeated at EOT. The median MRI-PDFF at baseline was 9.7% and 9.0%, respectively. At EOT, empagliflozin group had a greater drop in median MRI-PDFF than placebo group (–2.49% vs –1.43%; p=0.025), with a trend of resolution of hepatic steatosis (44.9% vs 28.6%; p=0.094). Empagliflozin group had a greater drop in body weight (–2.7 vs –0.2kg; p<0.001), waist circumference (–2.0 vs –0.4cm; p=0.015), fasting glucose (–0.3 vs 0mmol/L; p<0.001) and ferritin (–126 vs –22pmol/L; p=0.030) compared with placebo group.
Conclusions: Treatment with empagliflozin for 52 weeks reduces hepatic fat content in MASLD subjects without DM, together with reduction in serum ferritin, fasting glucose and anthropometric parameters (body weight and waist circumference).
Funding: This work was funded by a research grant from the General Research Fund, Research Grant Council, The Government of the Hong Kong Special Administrative Region (Ref: 17110420).
Presenter
Speakers
University of Hong Kong Li Ka Shing Faculty of Medicine
Tracks
Related Products
ASSOCIATION BETWEEN GLYCEMIC CONTROL AND COLORECTAL ADENOMA AND CANCER RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A POPULATION-BASED COHORT STUDY
BACKGROUND: Whether glycemic control influences the risk of colonic adenoma and colorectal cancer (CRC) development is unknown…
VONOPRAZAN-BASED DUAL AND TRIPLE THERAPY VERSUS BISMUTH-BASED QUADRUPLE THERAPY AS FIRST-LINE THERAPY FOR HELICOBACTER PYLORI INFECTION IN CHINA: A THREE-ARMED, RANDOMIZED CLINICAL TRIAL
BACKGROUND AND AIM: We aimed to compare efficacy of vonoprazan-based therapies and bismuth-based quadruple therapy as first-line treatment for _Helicobacter pylori_ (_H. pylori_) infection in Southern China, where high primary resistance rates of clarithromycin and levofloxacin (>30%) exist…
Barry Marshall (Nobel Laureate 2005) and Adrienne Marshall Lecture: Latest Advances and Challenges in Helicobacter pylori Screening and Eradication
Chronic Helicobacter pylori (HP) infection is the leading cause of gastric cancer and other adverse outcomes such as peptic ulcer disease. Emerging antibiotic resistance poses a substantial challenge against effective eradication of this organism…
AASLD Presidential Plenary
ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS WITH CIRRHOSIS AND HEPATOCELLULAR CANCER IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
